| Aims:To observe the the clinical curative effect of transcatheter arterial chemoembolization combined with antiviral therapy in patients with hepatitis B virus-associated hepatocellular carcinoma,whether explicitly TACE combined with antiviral therapy may enhance the patient ’s survival condition, which provides a basis for further improvement of clinical treatment.Methods:The patients with hepatitis B virus-associated hepatocellular carcinoma are collected from January 2011 to December 2013 who were in the second affiliated hospital of Da Lian Medical University. A total of 79 consecutive HBV-related HCC patients undergoing TACE were randomized to two groups:the group of receiving transcatheter arterial chemoembolization combined with antiviral therapy( treatment group), a total of 38 patients;the group of receiving transcatheter arterial chemoembolization but no antiviral therapy(control group),a total of 41 patients.Follow up was every 3 months. Compare and analyse the information on the incidence of HBV reactivation,AFP,ALT, AST, HBV DNA and so on of the two groups.Results:1.There were 30 patients completed the follow-up for 12 months in the group of receiving transcatheter arterial chemoembolization combined with antiviral therapy.There were 33 patients completed the follow-up for 12 months in the control group.2.the differences of age, sexuality,ALT, AST, TB, PT, the level of HBV DNA,et al,were not statistically significant before treatment between the observed and controlgroups(P>0.05).3. After treatment,at 3 months and 6 months,the differences of ALT, AST, AFP between the two groups were not statistically significant(P>0.05),but at 12 months,there was statistical significance(P<0.05).4.In the follow-up period of 12 months after TACE, there were 9 patients of HBV reactivation in the control group and 2 patients in the treatment group, the difference between two groups was statistically significant(P<0.05).The differences of HBV DNA between the two groups were not statistically significant at 3 months(P>0.05),but at 6months and 12 months, there was statistical significance(P<0.05).5.HBV-DNA negative rate were 16.70%, 40.00%, 43.30% of the treatment group at3 months?6 months?12 months, but,3.03%,12.10%,12.10% of the control group at 3months?6 months?12 months.After treatment, at 3 months,the differences of HBV-DNA negative rate between the two groups were not statistically significant(P=0.066>0.05),but at 6 months and 12 months,it was statistical significant between the two groups(P<0.05).Conclusions:TACE may can lead to HBV reactivation,while nucleoside drugs could inhibit hepatitis B-virus reactivation.TACE with nucleoside analogues(acid)antiviral treatment could have good clinical effect and improve patients’ liver function in patients with hepatitis B virus-associated hepatocellular carcinoma. |
